Results 131 to 140 of about 993 (163)

The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics. [PDF]

J Antimicrob Chemother
Andes D, Brüggemann RJ, Flanagan S, Lepak AJ, Lewis RE, Ong V, Rubino CM, Sandison T.   +7 more
europepmc   +1 more source

<i>In vitro</i> activity of novel antifungals, natamycin, and terbinafine against <i>Fusarium</i>. [PDF]

Antimicrob Agents Chemother
Garbe E, Ullah A, Aldejohann AM, Kurzai O, Janevska S, Walther G.   +5 more
europepmc   +1 more source

The personalized treatment of invasive candidiasis still has a long way to go. [PDF]

Crit Care
Wang L, Xu C, Chen Y, Zhou M, Li R, Lin B, Yu Y.   +6 more
europepmc   +1 more source

Rezafungin in special populations with candidaemia and/or invasive candidiasis

Journal of Infection
Achieving and maintaining therapeutic drug exposures with antifungals can be challenging in special patient populations, such as those with organ dysfunction (liver or kidney) or obesity, or elderly patients, due to dose-exposure relationships and potential drug-drug interactions.
George Thompson, Oliver A Cornely, Riina Richardson   +2 more
exaly   +4 more sources